Clinical Trials

Burkitt lymphoma

Displaying 2 studies

An Open-label Study To Assess The Anti-Tumor Activity And Safety Of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody, In Patients With Relapsed Or Refractory B-cell Non-Hodgkin Lymphoma Rochester, MN

The primary objective of this study is to assess the anti-tumor activity of single agent REGN1979 as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) non-Hodgkin lymphoma (B-NHL) subgroups.
A Study Investigating The Safety, Tolerability, Pharmacokinetics, And Effectiveness Of Mosunetuzumab (BTCT4465A) In Combination With CHOP Or CHP-Polatuzumab Vedotin In Participants With B-Cell Non-Hodgkin Lymphoma Rochester, MN

The purpose of this study is to evaluate the safety, pharmacokinetics, and preliminary effectiveness of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).